BTIG downgrades Prometheus Biosciences to Neutral

  • Investing.com
BTIG downgrades Prometheus Biosciences to Neutral

A BTIG analyst downgraded Prometheus Biosciences (NASDAQ: RXDX) from Buy to Neutral with a price target of $No data.

Prior to this rating, Prometheus Biosciences had 11 buy ratings, 0 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Prometheus Biosciences, click here. For more news on Prometheus Biosciences, click here.

Prometheus Biosciences's stock price closed at $114.01. They are up 0% in the last month and up 263.44% in the last 12 months.

According to Investing Pro, Prometheus Biosciences's fair value is $67.80, a downside of 40.53%. Prometheus Biosciences's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Prometheus Biosciences's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles